A Phase 2 Study of PH284 in Cachexia
Latest Information Update: 28 Jan 2025
Price :
$35 *
At a glance
- Drugs PH 284 (Primary)
- Indications Cachexia
- Focus Therapeutic Use
- 28 Jan 2025 New trial record
- 14 Jan 2025 According to a VistaGen Therapeutics media release, the company is assessing completed studies and studies they believe are necessary to support a U.S. Investigational New Drug application for potential further Phase 2 clinical development of PH284 for the treatment of cachexia.